ID   RASN_HUMAN              Reviewed;         189 AA.
AC   P01111; Q14971; Q15104; Q15282;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   26-FEB-2020, entry version 228.
DE   RecName: Full=GTPase NRas;
DE   AltName: Full=Transforming protein N-Ras;
DE   Flags: Precursor;
GN   Name=NRAS; Synonyms=HRAS1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6616621; DOI=10.1016/0092-8674(83)90390-2;
RA   Taparowsky E., Shimizu K., Goldfarb M., Wigler M.;
RT   "Structure and activation of the human N-ras gene.";
RL   Cell 34:581-586(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2991860; DOI=10.1093/nar/13.14.5255;
RA   Hall A., Brown R.;
RT   "Human N-ras: cDNA cloning and gene structure.";
RL   Nucleic Acids Res. 13:5255-5268(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Fibrosarcoma;
RX   PubMed=6086315; DOI=10.1002/j.1460-2075.1984.tb01970.x;
RA   Brown R., Marshall C.J., Pennie S.G., Hall A.;
RT   "Mechanism of activation of an N-ras gene in the human fibrosarcoma cell
RT   line HT1080.";
RL   EMBO J. 3:1321-1326(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Lung carcinoma;
RX   PubMed=6587382; DOI=10.1073/pnas.81.12.3670;
RA   Yuasa Y., Gol R.A., Chang A., Chiu I.-M., Reddy E.P., Tronick S.R.,
RA   Aaronson S.A.;
RT   "Mechanism of activation of an N-ras oncogene of SW-1271 human lung
RT   carcinoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:3670-3674(1984).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE OF 1-96, AND VARIANT CYS-12.
RC   TISSUE=Leukemia;
RX   PubMed=2998510;
RA   Hirai H., Tanaka S., Azuma M., Anraku Y., Kobayashi Y., Fujisawa M.,
RA   Okabe T., Urabe A., Takaku F.;
RT   "Transforming genes in human leukemia cells.";
RL   Blood 66:1371-1378(1985).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 1-29 AND 43-78.
RX   PubMed=1970154;
RA   Yuasa Y., Kamiyama T., Kato M., Iwama T., Ikeuchi T., Tonomura A.;
RT   "Transforming genes from familial adenomatous polyposis patient cells
RT   detected by a tumorigenicity assay.";
RL   Oncogene 5:589-596(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-96.
RX   PubMed=3856237; DOI=10.1073/pnas.82.3.879;
RA   Gambke C., Hall A., Moroni C.;
RT   "Activation of an N-ras gene in acute myeloblastic leukemia through somatic
RT   mutation in the first exon.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:879-882(1985).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-96.
RC   TISSUE=Bone marrow;
RX   PubMed=3295562; DOI=10.1038/327430a0;
RA   Hirai H., Kobayashi Y., Mano H., Hagiwara K., Maru Y., Omine M.,
RA   Mizoguchi H., Nishida J., Takaku F.;
RT   "A point mutation at codon 13 of the N-ras oncogene in myelodysplastic
RT   syndrome.";
RL   Nature 327:430-432(1987).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 60-96, AND VARIANT ARG-61.
RX   PubMed=3276402;
RA   Raybaud F., Noguchi T., Marics I., Adelaide J., Planche J., Batoz M.,
RA   Aubet C., de Lapeyriere O., Birnbaum D.;
RT   "Detection of a low frequency of activated ras genes in human melanomas
RT   using a tumorigenicity assay.";
RL   Cancer Res. 48:950-953(1988).
RN   [13]
RP   PALMITOYLATION AT CYS-181, AND ISOPRENYLATION AT CYS-186.
RX   PubMed=2661017; DOI=10.1016/0092-8674(89)90054-8;
RA   Hancock J.F., Magee A.I., Childs J.E., Marshall C.J.;
RT   "All ras proteins are polyisoprenylated but only some are palmitoylated.";
RL   Cell 57:1167-1177(1989).
RN   [14]
RP   INVOLVEMENT IN NMTC2, AND VARIANT NMTC2 ARG-61.
RX   PubMed=12727991; DOI=10.1210/jc.2002-021907;
RA   Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W. II,
RA   Tallini G., Kroll T.G., Nikiforov Y.E.;
RT   "RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors:
RT   evidence for distinct molecular pathways in thyroid follicular carcinoma.";
RL   J. Clin. Endocrinol. Metab. 88:2318-2326(2003).
RN   [15]
RP   PALMITOYLATION AT CYS-181.
RX   PubMed=16000296; DOI=10.1074/jbc.m504113200;
RA   Swarthout J.T., Lobo S., Farh L., Croke M.R., Greentree W.K.,
RA   Deschenes R.J., Linder M.E.;
RT   "DHHC9 and GCP16 constitute a human protein fatty acyltransferase with
RT   specificity for H- and N-Ras.";
RL   J. Biol. Chem. 280:31141-31148(2005).
RN   [16]
RP   PALMITOYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=15705808; DOI=10.1126/science.1105654;
RA   Rocks O., Peyker A., Kahms M., Verveer P.J., Koerner C., Lumbierres M.,
RA   Kuhlmann J., Waldmann H., Wittinghofer A., Bastiaens P.I.H.;
RT   "An acylation cycle regulates localization and activity of palmitoylated
RT   Ras isoforms.";
RL   Science 307:1746-1752(2005).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   INTERACTION WITH RASSF7.
RX   PubMed=21278800; DOI=10.1038/cdd.2010.137;
RA   Takahashi S., Ebihara A., Kajiho H., Kontani K., Nishina H., Katada T.;
RT   "RASSF7 negatively regulates pro-apoptotic JNK signaling by inhibiting the
RT   activity of phosphorylated-MKK7.";
RL   Cell Death Differ. 18:645-655(2011).
RN   [19]
RP   SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-181, AND MUTAGENESIS OF
RP   CYS-181.
RX   PubMed=26701913; DOI=10.7554/elife.11306;
RA   Lin D.T., Conibear E.;
RT   "ABHD17 proteins are novel protein depalmitoylases that regulate N-Ras
RT   palmitate turnover and subcellular localization.";
RL   Elife 4:E11306-E11306(2015).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [21]
RP   UBIQUITINATION AT LYS-170.
RX   PubMed=30442762; DOI=10.1126/science.aap7607;
RA   Steklov M., Pandolfi S., Baietti M.F., Batiuk A., Carai P., Najm P.,
RA   Zhang M., Jang H., Renzi F., Cai Y., Abbasi Asbagh L., Pastor T.,
RA   De Troyer M., Simicek M., Radaelli E., Brems H., Legius E., Tavernier J.,
RA   Gevaert K., Impens F., Messiaen L., Nussinov R., Heymans S., Eyckerman S.,
RA   Sablina A.A.;
RT   "Mutations in LZTR1 drive human disease by dysregulating RAS
RT   ubiquitination.";
RL   Science 362:1177-1182(2018).
RN   [22]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-89, MUTAGENESIS OF
RP   SER-89, VARIANT ARG-61, AND CHARACTERIZATION OF VARIANT ARG-61.
RX   PubMed=30712867; DOI=10.1016/j.cell.2019.01.002;
RA   Yin C., Zhu B., Zhang T., Liu T., Chen S., Liu Y., Li X., Miao X., Li S.,
RA   Mi X., Zhang J., Li L., Wei G., Xu Z.X., Gao X., Huang C., Wei Z.,
RA   Goding C.R., Wang P., Deng X., Cui R.;
RT   "Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven
RT   melanomagenesis.";
RL   Cell 176:1113-1127(2019).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1-172 IN COMPLEX WITH GDP.
RA   Nedyalkova L., Tong Y., Tempel W., Shen L., Loppnau P., Arrowsmith C.H.,
RA   Edwards A.M., Bountra C., Weigelt J., Bochkarev A., Park H.;
RT   "Crystal structure of the human NRAS GTPase bound with GDP.";
RL   Submitted (MAR-2008) to the PDB data bank.
RN   [24]
RP   VARIANT COLORECTAL CANCER ARG-13.
RX   PubMed=3102434;
RA   Nitta N., Ochiai M., Nagao M., Sugimura T.;
RT   "Amino-acid substitution at codon 13 of the N-ras oncogene in rectal cancer
RT   in a Japanese patient.";
RL   Jpn. J. Cancer Res. 78:21-26(1987).
RN   [25]
RP   VARIANTS JMML ASP-12 AND ASP-13.
RX   PubMed=17332249; DOI=10.1182/blood-2006-09-046649;
RA   Matsuda K., Shimada A., Yoshida N., Ogawa A., Watanabe A., Yajima S.,
RA   Iizuka S., Koike K., Yanai F., Kawasaki K., Yanagimachi M., Kikuchi A.,
RA   Ohtsuka Y., Hidaka E., Yamauchi K., Tanaka M., Yanagisawa R., Nakazawa Y.,
RA   Shiohara M., Manabe A., Kojima S., Koike K.;
RT   "Spontaneous improvement of hematologic abnormalities in patients having
RT   juvenile myelomonocytic leukemia with specific RAS mutations.";
RL   Blood 109:5477-5480(2007).
RN   [26]
RP   VARIANT RALD ASP-13.
RX   PubMed=17517660; DOI=10.1073/pnas.0702975104;
RA   Oliveira J.B., Bidere N., Niemela J.E., Zheng L., Sakai K., Nix C.P.,
RA   Danner R.L., Barb J., Munson P.J., Puck J.M., Dale J., Straus S.E.,
RA   Fleisher T.A., Lenardo M.J.;
RT   "NRAS mutation causes a human autoimmune lymphoproliferative syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8953-8958(2007).
RN   [27]
RP   VARIANTS CMNS ARG-13 AND ARG-61.
RX   PubMed=18633438; DOI=10.1038/jid.2008.203;
RA   Dessars B., De Raeve L.E., Morandini R., Lefort A., El Housni H.,
RA   Ghanem G.E., Van den Eynde B.J., Ma W., Roseeuw D., Vassart G., Libert F.,
RA   Heimann P.;
RT   "Genotypic and gene expression studies in congenital melanocytic nevi:
RT   insight into initial steps of melanotumorigenesis.";
RL   J. Invest. Dermatol. 129:139-147(2009).
RN   [28]
RP   VARIANTS NS6 ILE-50 AND GLU-60, AND CHARACTERIZATION OF VARIANTS NS6 ILE-50
RP   AND GLU-60.
RX   PubMed=19966803; DOI=10.1038/ng.497;
RA   Cirstea I.C., Kutsche K., Dvorsky R., Gremer L., Carta C., Horn D.,
RA   Roberts A.E., Lepri F., Merbitz-Zahradnik T., Konig R., Kratz C.P.,
RA   Pantaleoni F., Dentici M.L., Joshi V.A., Kucherlapati R.S., Mazzanti L.,
RA   Mundlos S., Patton M.A., Silengo M.C., Rossi C., Zampino G., Digilio C.,
RA   Stuppia L., Seemanova E., Pennacchio L.A., Gelb B.D., Dallapiccola B.,
RA   Wittinghofer A., Ahmadian M.R., Tartaglia M., Zenker M.;
RT   "A restricted spectrum of NRAS mutations causes Noonan syndrome.";
RL   Nat. Genet. 42:27-29(2010).
RN   [29]
RP   VARIANTS KNEN ASP-12; LEU-34 AND ARG-61.
RX   PubMed=22499344; DOI=10.1136/jmedgenet-2011-100637;
RA   Hafner C., Toll A., Gantner S., Mauerer A., Lurkin I., Acquadro F.,
RA   Fernandez-Casado A., Zwarthoff E.C., Dietmaier W., Baselga E., Parera E.,
RA   Vicente A., Casanova A., Cigudosa J., Mentzel T., Pujol R.M.,
RA   Landthaler M., Real F.X.;
RT   "Keratinocytic epidermal nevi are associated with mosaic RAS mutations.";
RL   J. Med. Genet. 49:249-253(2012).
RN   [30]
RP   VARIANTS CMNS ARG-61 AND LYS-61, AND VARIANTS NCMS ARG-61 AND LYS-61.
RX   PubMed=23392294; DOI=10.1038/jid.2013.70;
RA   Kinsler V.A., Thomas A.C., Ishida M., Bulstrode N.W., Loughlin S., Hing S.,
RA   Chalker J., McKenzie K., Abu-Amero S., Slater O., Chanudet E., Palmer R.,
RA   Morrogh D., Stanier P., Healy E., Sebire N.J., Moore G.E.;
RT   "Multiple congenital melanocytic nevi and neurocutaneous melanosis are
RT   caused by postzygotic mutations in codon 61 of NRAS.";
RL   J. Invest. Dermatol. 133:2229-2236(2013).
CC   -!- FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase
CC       activity. {ECO:0000269|PubMed:30712867}.
CC   -!- ACTIVITY REGULATION: Alternates between an inactive form bound to GDP
CC       and an active form bound to GTP. Activated by a guanine nucleotide-
CC       exchange factor (GEF) and inactivated by a GTPase-activating protein
CC       (GAP).
CC   -!- SUBUNIT: Interacts (active GTP-bound form preferentially) with RGS14
CC       (By similarity). Interacts (active GTP-bound form) with RASSF7
CC       (PubMed:21278800). {ECO:0000250|UniProtKB:Q04970,
CC       ECO:0000269|PubMed:21278800}.
CC   -!- INTERACTION:
CC       P15056:BRAF; NbExp=3; IntAct=EBI-721993, EBI-365980;
CC       P28028:Braf (xeno); NbExp=2; IntAct=EBI-721993, EBI-2584830;
CC       P04049:RAF1; NbExp=5; IntAct=EBI-721993, EBI-365996;
CC       Q99N57:Raf1 (xeno); NbExp=2; IntAct=EBI-721993, EBI-397757;
CC       P52306-5:RAP1GDS1; NbExp=4; IntAct=EBI-721993, EBI-12832744;
CC       Q13671:RIN1; NbExp=5; IntAct=EBI-721993, EBI-366017;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15705808,
CC       ECO:0000269|PubMed:26701913}; Lipid-anchor
CC       {ECO:0000269|PubMed:15705808, ECO:0000269|PubMed:26701913}; Cytoplasmic
CC       side {ECO:0000269|PubMed:15705808, ECO:0000269|PubMed:26701913}. Golgi
CC       apparatus membrane {ECO:0000269|PubMed:15705808,
CC       ECO:0000269|PubMed:26701913}; Lipid-anchor
CC       {ECO:0000269|PubMed:15705808, ECO:0000269|PubMed:26701913}.
CC       Note=Shuttles between the plasma membrane and the Golgi apparatus.
CC       {ECO:0000269|PubMed:15705808, ECO:0000269|PubMed:26701913}.
CC   -!- PTM: Palmitoylated by the ZDHHC9-GOLGA7 complex (PubMed:16000296).
CC       Depalmitoylated by ABHD17A, ABHD17B and ABHD17C (PubMed:26701913). A
CC       continuous cycle of de- and re-palmitoylation regulates rapid exchange
CC       between plasma membrane and Golgi (PubMed:16000296, PubMed:15705808,
CC       PubMed:2661017, PubMed:26701913). {ECO:0000269|PubMed:15705808,
CC       ECO:0000269|PubMed:16000296, ECO:0000269|PubMed:2661017,
CC       ECO:0000269|PubMed:26701913}.
CC   -!- PTM: Acetylation at Lys-104 prevents interaction with guanine
CC       nucleotide exchange factors (GEFs). {ECO:0000250|UniProtKB:P01116}.
CC   -!- PTM: Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at
CC       Lys-170 in a non-degradative manner, leading to inhibit Ras signaling
CC       by decreasing Ras association with membranes.
CC       {ECO:0000305|PubMed:30442762}.
CC   -!- PTM: Phosphorylation at Ser-89 by STK19 enhances NRAS-association with
CC       its downstream effectors. {ECO:0000269|PubMed:30712867}.
CC   -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An
CC       aggressive pediatric myelodysplastic syndrome/myeloproliferative
CC       disorder characterized by malignant transformation in the hematopoietic
CC       stem cell compartment with proliferation of differentiated progeny.
CC       Patients have splenomegaly, enlarged lymph nodes, rashes, and
CC       hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Noonan syndrome 6 (NS6) [MIM:613224]: A form of Noonan
CC       syndrome, a disease characterized by short stature, facial dysmorphic
CC       features such as hypertelorism, a downward eyeslant and low-set
CC       posteriorly rotated ears, and a high incidence of congenital heart
CC       defects and hypertrophic cardiomyopathy. Other features can include a
CC       short neck with webbing or redundancy of skin, deafness, motor delay,
CC       variable intellectual deficits, multiple skeletal defects,
CC       cryptorchidism, and bleeding diathesis. Individuals with Noonan
CC       syndrome are at risk of juvenile myelomonocytic leukemia, a
CC       myeloproliferative disorder characterized by excessive production of
CC       myelomonocytic cells. {ECO:0000269|PubMed:19966803}. Note=The disease
CC       is caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: RAS-associated autoimmune leukoproliferative disorder (RALD)
CC       [MIM:614470]: A disorder of apoptosis, characterized by chronic
CC       accumulation of non-malignant lymphocytes, defective lymphocyte
CC       apoptosis, and an increased risk for the development of hematologic
CC       malignancies. {ECO:0000269|PubMed:17517660}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Melanocytic nevus syndrome, congenital (CMNS) [MIM:137550]: A
CC       syndrome characterized by congenital pigmentary skin lesions which can
CC       occur at any site and can cover most of the body surface. These lesions
CC       may or may not be hairy. Congenital melanocytic nevi are associated
CC       with neuromelanosis (the presence of melanin-producing cells within the
CC       brain parenchyma or leptomeninges). Less commonly they are associated
CC       with malignant melanoma in childhood, both in the skin and the central
CC       nervous system. CMNS patients also tend to have a characteristic facial
CC       appearance, including wide or prominent forehead, periorbital fullness,
CC       small short nose with narrow nasal bridge, round face, full cheeks,
CC       prominent premaxilla, and everted lower lip.
CC       {ECO:0000269|PubMed:18633438, ECO:0000269|PubMed:23392294}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Melanosis, neurocutaneous (NCMS) [MIM:249400]: A rare
CC       congenital disease characterized by the presence of giant or multiple
CC       melanocytic nevi on the skin, foci of melanin-producing cells within
CC       the brain parenchyma, and infiltration of leptomeninges by abnormal
CC       melanin deposits. Neurologic abnormalities include seizures,
CC       hydrocephalus, arachnoid cysts, tumors, and syringomyelia. Some
CC       patients may develop malignant melanoma. {ECO:0000269|PubMed:23392294}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Keratinocytic non-epidermolytic nevus (KNEN) [MIM:162900]:
CC       Epidermal nevi of the common, non-organoid and non-epidermolytic type
CC       are benign skin lesions and may vary in their extent from a single
CC       (usually linear) lesion to widespread and systematized involvement.
CC       They may be present at birth or develop early during childhood.
CC       {ECO:0000269|PubMed:22499344}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Thyroid cancer, non-medullary, 2 (NMTC2) [MIM:188470]: A form
CC       of non-medullary thyroid cancer (NMTC), a cancer characterized by
CC       tumors originating from the thyroid follicular cells. NMTCs represent
CC       approximately 95% of all cases of thyroid cancer and are classified
CC       into papillary, follicular, Hurthle cell, and anaplastic neoplasms.
CC       {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Mutations which change AA 12, 13 or 61 activate the
CC       potential of Ras to transform cultured cells and are implicated in a
CC       variety of human tumors.
CC   -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NRASID92.html";
CC   -!- WEB RESOURCE: Name=NRASbase; Note=NRAS mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/NRASbase/";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/nras/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=RAS proteins entry;
CC       URL="https://en.wikipedia.org/wiki/RAS_proteins";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X02751; CAA26529.1; -; mRNA.
DR   EMBL; X00642; CAA25269.1; -; Genomic_DNA.
DR   EMBL; X00643; CAA25270.1; -; Genomic_DNA.
DR   EMBL; X00644; CAA25271.1; -; Genomic_DNA.
DR   EMBL; X00645; CAA25272.1; -; Genomic_DNA.
DR   EMBL; L00043; AAA60255.1; -; Genomic_DNA.
DR   EMBL; L00040; AAA60255.1; JOINED; Genomic_DNA.
DR   EMBL; L00041; AAA60255.1; JOINED; Genomic_DNA.
DR   EMBL; L00042; AAA60255.1; JOINED; Genomic_DNA.
DR   EMBL; AF493919; AAM12633.1; -; mRNA.
DR   EMBL; AY428630; AAQ94397.1; -; Genomic_DNA.
DR   EMBL; BC005219; AAH05219.1; -; mRNA.
DR   EMBL; M25898; AAA36548.1; -; Genomic_DNA.
DR   EMBL; X53291; CAA37384.1; -; Genomic_DNA.
DR   EMBL; X53292; CAA37384.1; JOINED; Genomic_DNA.
DR   EMBL; K03211; AAA36556.1; -; Genomic_DNA.
DR   EMBL; M10055; AAA36556.1; JOINED; Genomic_DNA.
DR   EMBL; X05565; CAA29079.1; -; Genomic_DNA.
DR   EMBL; X07440; CAA30320.1; -; Genomic_DNA.
DR   CCDS; CCDS877.1; -.
DR   PIR; A90839; TVHURA.
DR   PIR; I38149; I38149.
DR   RefSeq; NP_002515.1; NM_002524.4.
DR   PDB; 2N9C; NMR; -; A=1-17.
DR   PDB; 3CON; X-ray; 1.65 A; A=1-172.
DR   PDB; 5UHV; X-ray; 1.67 A; A=1-166.
DR   PDB; 6E6H; X-ray; 1.99 A; A=1-166.
DR   PDBsum; 2N9C; -.
DR   PDBsum; 3CON; -.
DR   PDBsum; 5UHV; -.
DR   PDBsum; 6E6H; -.
DR   SMR; P01111; -.
DR   BioGrid; 110952; 626.
DR   DIP; DIP-1058N; -.
DR   ELM; P01111; -.
DR   IntAct; P01111; 59.
DR   MINT; P01111; -.
DR   STRING; 9606.ENSP00000358548; -.
DR   BindingDB; P01111; -.
DR   ChEMBL; CHEMBL2079845; -.
DR   GuidetoPHARMACOLOGY; 2823; -.
DR   iPTMnet; P01111; -.
DR   PhosphoSitePlus; P01111; -.
DR   SwissPalm; P01111; -.
DR   BioMuta; NRAS; -.
DR   DMDM; 131883; -.
DR   OGP; P01111; -.
DR   EPD; P01111; -.
DR   jPOST; P01111; -.
DR   MassIVE; P01111; -.
DR   PaxDb; P01111; -.
DR   PeptideAtlas; P01111; -.
DR   PRIDE; P01111; -.
DR   ProteomicsDB; 51320; -.
DR   DNASU; 4893; -.
DR   Ensembl; ENST00000369535; ENSP00000358548; ENSG00000213281.
DR   GeneID; 4893; -.
DR   KEGG; hsa:4893; -.
DR   CTD; 4893; -.
DR   DisGeNET; 4893; -.
DR   GeneCards; NRAS; -.
DR   GeneReviews; NRAS; -.
DR   HGNC; HGNC:7989; NRAS.
DR   HPA; CAB010157; -.
DR   HPA; HPA049830; -.
DR   MalaCards; NRAS; -.
DR   MIM; 137550; phenotype.
DR   MIM; 162900; phenotype.
DR   MIM; 164790; gene.
DR   MIM; 188470; phenotype.
DR   MIM; 249400; phenotype.
DR   MIM; 607785; phenotype.
DR   MIM; 613224; phenotype.
DR   MIM; 614470; phenotype.
DR   neXtProt; NX_P01111; -.
DR   OpenTargets; ENSG00000213281; -.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   Orphanet; 86834; Juvenile myelomonocytic leukemia.
DR   Orphanet; 626; Large congenital melanocytic nevus.
DR   Orphanet; 2612; Linear nevus sebaceus syndrome.
DR   Orphanet; 411533; NON RARE IN EUROPE: Melanoma.
DR   Orphanet; 648; Noonan syndrome.
DR   Orphanet; 268114; RAS-associated autoimmune leukoproliferative disease.
DR   Orphanet; 357194; Selection of therapeutic option in colorectal cancer.
DR   Orphanet; 544260; Selection of therapeutic option in melanoma.
DR   PharmGKB; PA31768; -.
DR   eggNOG; KOG0395; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   GeneTree; ENSGT00940000158947; -.
DR   HOGENOM; CLU_041217_9_8_1; -.
DR   InParanoid; P01111; -.
DR   KO; K07828; -.
DR   OMA; NQGCMGL; -.
DR   OrthoDB; 1344247at2759; -.
DR   PhylomeDB; P01111; -.
DR   TreeFam; TF312796; -.
DR   Reactome; R-HSA-112412; SOS-mediated signalling.
DR   Reactome; R-HSA-1169092; Activation of RAS in B cells.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-167044; Signalling to RAS.
DR   Reactome; R-HSA-171007; p38MAPK events.
DR   Reactome; R-HSA-179812; GRB2 events in EGFR signaling.
DR   Reactome; R-HSA-180336; SHC1 events in EGFR signaling.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1.
DR   Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2.
DR   Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling.
DR   Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3.
DR   Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling.
DR   Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling.
DR   Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4.
DR   Reactome; R-HSA-5655253; Signaling by FGFR2 in disease.
DR   Reactome; R-HSA-5655291; Signaling by FGFR4 in disease.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-5658442; Regulation of RAS by GAPs.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-74751; Insulin receptor signalling cascade.
DR   Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases.
DR   Reactome; R-HSA-8851805; MET activates RAS signaling.
DR   Reactome; R-HSA-8853334; Signaling by FGFR3 fusions in cancer.
DR   Reactome; R-HSA-8853338; Signaling by FGFR3 point mutants in cancer.
DR   Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS.
DR   Reactome; R-HSA-9027284; Erythropoietin activates RAS.
DR   Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3.
DR   Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS.
DR   Reactome; R-HSA-9607240; FLT3 Signaling.
DR   Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ.
DR   Reactome; R-HSA-9649913; RAS GTPase cycle mutants.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   SignaLink; P01111; -.
DR   SIGNOR; P01111; -.
DR   ChiTaRS; NRAS; human.
DR   EvolutionaryTrace; P01111; -.
DR   GeneWiki; Neuroblastoma_RAS_viral_oncogene_homolog; -.
DR   GenomeRNAi; 4893; -.
DR   Pharos; P01111; Tchem.
DR   PRO; PR:P01111; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P01111; protein.
DR   Bgee; ENSG00000213281; Expressed in testis and 216 other tissues.
DR   ExpressionAtlas; P01111; baseline and differential.
DR   Genevisible; P01111; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:CACAO.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0019003; F:GDP binding; IBA:GO_Central.
DR   GO; GO:0005525; F:GTP binding; IBA:GO_Central.
DR   GO; GO:0003924; F:GTPase activity; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:MGI.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0007265; P:Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR020849; Small_GTPase_Ras-type.
DR   PANTHER; PTHR24070; PTHR24070; 1.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51421; RAS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell membrane; Disease mutation;
KW   Golgi apparatus; GTP-binding; Isopeptide bond; Lipoprotein; Membrane;
KW   Methylation; Nucleotide-binding; Palmitate; Phosphoprotein; Prenylation;
KW   Proto-oncogene; Reference proteome; Ubl conjugation.
FT   CHAIN           1..186
FT                   /note="GTPase NRas"
FT                   /id="PRO_0000043006"
FT   PROPEP          187..189
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000043007"
FT   NP_BIND         10..18
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|Ref.23"
FT   NP_BIND         29..30
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|Ref.23"
FT   NP_BIND         57..61
FT                   /note="GTP"
FT                   /evidence="ECO:0000255"
FT   NP_BIND         116..119
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|Ref.23"
FT   REGION          166..185
FT                   /note="Hypervariable region"
FT   MOTIF           32..40
FT                   /note="Effector region"
FT   MOD_RES         89
FT                   /note="Phosphoserine; by STK19"
FT                   /evidence="ECO:0000269|PubMed:30712867"
FT   LIPID           181
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:16000296,
FT                   ECO:0000269|PubMed:2661017, ECO:0000269|PubMed:26701913"
FT   LIPID           186
FT                   /note="S-farnesyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:2661017"
FT   CROSSLNK        170
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000305|PubMed:30442762"
FT   VARIANT         12
FT                   /note="G -> C (in leukemia; dbSNP:rs121913250)"
FT                   /evidence="ECO:0000269|PubMed:2998510"
FT                   /id="VAR_021194"
FT   VARIANT         12
FT                   /note="G -> D (in KNEN and JMML; dbSNP:rs121913237)"
FT                   /evidence="ECO:0000269|PubMed:17332249,
FT                   ECO:0000269|PubMed:22499344"
FT                   /id="VAR_071129"
FT   VARIANT         13
FT                   /note="G -> D (in RALD and JMML; dbSNP:rs121434596)"
FT                   /evidence="ECO:0000269|PubMed:17332249,
FT                   ECO:0000269|PubMed:17517660"
FT                   /id="VAR_063084"
FT   VARIANT         13
FT                   /note="G -> R (in CMNS and colorectal cancer; somatic
FT                   mutation; dbSNP:rs121434595)"
FT                   /evidence="ECO:0000269|PubMed:18633438,
FT                   ECO:0000269|PubMed:3102434"
FT                   /id="VAR_006845"
FT   VARIANT         34
FT                   /note="P -> L (in KNEN; dbSNP:rs397514553)"
FT                   /evidence="ECO:0000269|PubMed:22499344"
FT                   /id="VAR_071130"
FT   VARIANT         50
FT                   /note="T -> I (in NS6; hypermorphic mutation;
FT                   dbSNP:rs267606921)"
FT                   /evidence="ECO:0000269|PubMed:19966803"
FT                   /id="VAR_063085"
FT   VARIANT         60
FT                   /note="G -> E (in NS6; hypermorphic mutation;
FT                   dbSNP:rs267606920)"
FT                   /evidence="ECO:0000269|PubMed:19966803"
FT                   /id="VAR_063086"
FT   VARIANT         61
FT                   /note="Q -> K (in CMNS and NCMS; somatic mutation;
FT                   dbSNP:rs121913254)"
FT                   /evidence="ECO:0000269|PubMed:23392294"
FT                   /id="VAR_006846"
FT   VARIANT         61
FT                   /note="Q -> R (in CMNS, NCMS, KNEN and NMTC2; also found in
FT                   lung carcinoma cell and melanoma; impaired GTP hydrolysis
FT                   activity, trapping NRAS in a constitutive GTP-bound active
FT                   conformation; promotes melanomagenesis; dbSNP:rs11554290)"
FT                   /evidence="ECO:0000269|PubMed:12727991,
FT                   ECO:0000269|PubMed:18633438, ECO:0000269|PubMed:22499344,
FT                   ECO:0000269|PubMed:23392294, ECO:0000269|PubMed:30712867,
FT                   ECO:0000269|PubMed:3276402"
FT                   /id="VAR_006847"
FT   MUTAGEN         89
FT                   /note="S->A: Abolished phosphorylation by STK19."
FT                   /evidence="ECO:0000269|PubMed:30712867"
FT   MUTAGEN         164
FT                   /note="R->A: Loss of GTP-binding activity."
FT   MUTAGEN         181
FT                   /note="C->S: Loss of plasma membrane localization."
FT                   /evidence="ECO:0000269|PubMed:26701913"
FT   STRAND          2..9
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   HELIX           16..25
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   STRAND          38..46
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   STRAND          49..57
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   HELIX           62..64
FT                   /evidence="ECO:0000244|PDB:5UHV"
FT   HELIX           65..71
FT                   /evidence="ECO:0000244|PDB:5UHV"
FT   TURN            72..74
FT                   /evidence="ECO:0000244|PDB:5UHV"
FT   STRAND          76..83
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   HELIX           87..104
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   STRAND          111..116
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   HELIX           127..137
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   STRAND          141..143
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   TURN            146..148
FT                   /evidence="ECO:0000244|PDB:3CON"
FT   HELIX           152..166
FT                   /evidence="ECO:0000244|PDB:3CON"
SQ   SEQUENCE   189 AA;  21229 MW;  6898D3F6815B1EC7 CRC64;
     MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG
     QEEYSAMRDQ YMRTGEGFLC VFAINNSKSF ADINLYREQI KRVKDSDDVP MVLVGNKCDL
     PTRTVDTKQA HELAKSYGIP FIETSAKTRQ GVEDAFYTLV REIRQYRMKK LNSSDDGTQG
     CMGLPCVVM
//
